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HeterogeneityMiRNA-34a is considered as a potential prognostic marker for glioma, as studies suggest that its
expression negatively correlates with patient survival in grade III and IV glial tumors. Here, we show
that expression of miR-34a was decreased in a graded manner in glioma and glioma stem cell-lines
as compared to normal brain tissues. Ectopic expression of miR-34a in glioma stem cell-lines HNGC-
2 and NSG-K16 decreased the proliferative and migratory potential of these cells, induced cell cycle
arrest and caused apoptosis. Notably, the miR-34a glioma cells formed signiﬁcantly smaller xeno-
grafts in immuno-deﬁcient mice as compared with control glioma stem cell-lines. Here, using a bio-
informatics approach and various biological assays, we identify Rictor, as a novel target for miR-34a
in glioma stem cells. Rictor, a deﬁning component of mTORC2 complex, is involved in cell survival
signaling. mTORC2 lays downstream of Akt, and thus is a direct activator of Akt. Our earlier studies
have elaborated on role of Rictor in glioma invasion (Das et al., 2011). Here, we demonstrate that
miR34a over-expression in glioma stem cells profoundly decreased levels of p-AKT (Ser473),
increased GSK-3b levels and targeted for degradation b-catenin, an important mediator of Wnt sig-
naling pathway. This led to diminished levels of the Wnt effectors cyclin D1 and c-myc. Collectively,
we show that the tumor suppressive function of miR-34a in glioblastoma is mediated via Rictor,
which through its effects on AKT/mTOR pathway and Wnt signaling causes pronounced effects on
glioma malignancy.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Gliomas are the most common tumors of central nervous sys-
tem (CNS). Amongst the different grades of glioma, glioblastoma
multiforme (GBM), classiﬁed by World Health Organization
(WHO) as grade IV glioma is particularly aggressive, inﬁltrativeand vascularized tumor with patients showing a one year median
survival. Major challenges in GBM therapy are associated with
location of the disease and high level of inter- and intra-tumoral
heterogeneity, leading to accumulation of several genetic changes
over time [1]. The heterogeneity possibly is an outcome of exis-
tence of hierarchy of subpopulations of tumorigenic cancer stem
cells and their non-tumorigenic progeny [2]. The cell of origin for
glioma is considered to be a neural stem cell with propensity to
be transformed into a glioma stem cell (GSC) also referred to as a
glioma initiating cell (GIC) [3]. This transformation to a glioma
stem cell state involves aberrant activation of signaling pathways
along with multiplicity of abnormal events at genetic and epige-
netic levels including alterations in class of non-coding RNAs
known as microRNAs.
MicroRNAs (miRNAs) are of 21–25 nucleotides size and are
involved in post-transcriptional control of gene expression [4].
They regulate protein synthesis by base pairing to partially
complementary sequences in the 30 un-translated regions (UTRs)
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execute their function in a dynamic and context-dependent man-
ner by targeting diverse downstream target genes from transcrip-
tional factors to epigenetic regulators. In GBM, several miRNAs
have either oncogenes or tumor suppressor genes as their targets.
A comprehensive overview on the expression proﬁles and func-
tions of miRNAs in GBM specify that compared to normal brain tis-
sues about 253 miRNAs are up-regulated, about 95 are down-
regulated and 17 show disputed status. Importantly, about 85%
of these miRNAs are not yet functionally characterized [5]. The
overexpressed miRNAs include few like miR-17, miR-21, miR-93,
and miRNAs – 221/222 that inﬂuence processes like proliferation,
in vivo tumor growth, invasiveness and angiogenesis. The miRNAs
with growth suppressive properties that are down-regulated in
GBM include miR-7, miR-45, miR-29b, miR-101, miR-124, miR-
145 and miR-34a [6–8].
MicroRNA-34a is mapped to a region of chromosome 1p36.23 in
human and shows deviant expression in multiple cancer types like
neuroblastoma [9,10], colon cancer [11], prostate [12] and pancre-
atic cancer [13]. It is shown to be a transcriptional target and val-
idated component of the p53 tumor suppressor network and a legit
tumor suppressor for glioma [14]. Studies showed that higher miR-
34a levels were associated with wild-type p53 tumors possessing
lower Bcl-2 expression levels than in tissues with lower miR-34a
expression [15]. The role of miR-34a as a tumor suppressive RNA
was demonstrated for glioma stem cells with Notch1/2 and
c-Met as its functional targets. Recently, Musashi-1 and platelet-
derived growth factor receptor-a (PDGFRA) [16,17] were identiﬁed
as miR-34a targets and hence miR-34a loss in GBM was considered
responsible for increased PDGF signaling.
The miRNA expression signatures both characterize and con-
tribute to the phenotypic diversity of glioblastoma subclasses.
Recent work on genome wide proﬁling with help of the cancer gen-
ome atlas (TCGA) [18] database, using various parameters like copy
number analysis, miRNA and mRNA analysis, mutational and
methylation analysis, have all led to generation of GBM tumor sub-
type speciﬁc network proﬁles [19–21]. These sub-types are classi-
cal, mesenchymal, neural, and pro-neural. Amongst these four
subtypes, the tumors with mesenchymal GBM subtype are aggres-
sive in nature and negatively correlate with patient survival [22].
Several studies have identiﬁed microRNAs as potent regulators of
subclass-speciﬁc gene expression networks in glioblastoma [23].
They serve as important determinants of glioblastoma subclasses
through their ability to regulate developmental growth and differ-
entiation programs in several transformed neural precursor cell-
types.
In our previous studies, we reported molecular mechanisms for
transformation of non-tumorigenic neural stem cell-line HNGC-1
to tumorigenic glioma cancer stem cell line HNGC-2 [24]. Using
this cell system we identiﬁed differentially expressed miRNAs that
were speciﬁcally altered during the transformation event. Previ-
ously, we demonstrated role of miR-145 as a tumor suppressor
in GBM [8]. In this report, we have characterized glioma stem
cell-lines – HNGC-2 and NSG-K16 as belonging to the mesenchy-
mal sub-type and shown that miR-34a possesses tumor suppres-
sive function for this glioma sub-type. More importantly, we
have identiﬁed Rictor, a component of the mTORC2 complex, as a
novel target for miR-34a and established that its over-expression
contributes to the oncogenic properties of this malignancy. Next,
we show that Rictor by inducing AKT phosphorylation inhibits
GSK3b activity leading to nuclear activation of b-catenin followed
by activation of Wnt signaling pathway. The enhanced tumorigenic
potential and invasiveness of glioma stem cells is thereby mainly
contributed through activation of Akt and Wnt pathways caused
due to loss of miR-34a.2. Materials and methods
2.1. Tissue samples and clinical data
This study was approved by the Institutional Ethics Committee
(IEC) of National Centre for Cell Science (NCCS), Pune, India and
KEM Hospital, Mumbai, India. Human glioma tissue samples were
collected from KEM Hospital, Mumbai (n = 32) and classiﬁed by a
neuro-pathologist for respective grades of glioma usingWHO crite-
ria (Table S1). The tissue samples comprised of 13 low and 19 high
grade glioma tumors as well as normal brain tissues (n = 3) from
epileptic resections. Informed consent was sought from the
patients for use of tissues in this study. The tumor tissue samples
were used for establishment of long term glioma cultures and
RNA studies.
2.2. Cell culture
The non-tumorigenic neural stem cell-line HNGC-1 and other
glioma stem cell lines HNGC-2 [24] and NSG-K16 [25] were estab-
lished by us and maintained as described previously. Brieﬂy,
HNGC-2 and NSG-K16 cells were cultured in Dulbecco’s modiﬁed
Eagle’s (DMEM)/Ham’s F12 medium (1:1) (Invitrogen, Carlsbad,
CA, USA) with 1 B27 supplement (Invitrogen), epidermal growth
factor (EGF) (10 ng/mL) (Invitrogen), basic ﬁbroblast growth factor
(bFGF) (20 ng/mL) (Invitrogen), 1 non-essential amino acids
(NEAA) (Invitrogen), and 1 Glutamax (Invitrogen) at 37 C with
5% CO2 in a humidiﬁed incubator.
2.3. RNA extraction and quantitative real-time PCR
The tissue samples were homogenized by gentle MACS™ disso-
ciator (MACS Miltenyi Biotec, Auburn, CA, USA) and total RNA was
extracted from tissues and cells using Trizol Reagent (Invitrogen)
according to manufacturer’s protocol. The RNA concentration was
determined with a Biophotometer (Eppendorf, Hamburg, Ger-
many). With help of SuperScript III First strand synthesis system
(Invitrogen), 100 ng of total RNA was reverse transcribed into
cDNA using miR-34a speciﬁc stem-loop primers (Table S2).
Expression of mature miR-34a was quantiﬁed using SYBR green
master mix (Applied Biosystems, Foster City, CA, USA) using 7500
Fast Real Time PCR System (Applied Biosystems). The ampliﬁcation
reaction (10 lL) consisted of 2 SYBR green master mix, gene-spe-
ciﬁc primers and cDNA. Fold changes in gene expression were cal-
culated using 2DDCt method with 18S rRNA serving as an internal
control.
2.4. Vectors and transfections
Mir-34a stable clones were generated in both HNGC-2 and NSG-
K16 cell-lines by stable transfection using Lipofectamine 2000
(Invitrogen) according to manufacturer’s protocol. The level of
miR-34a expression was detected in stable miR-34 over-expressing
HNGC-2 and NSG-K16 cell-lines. For luciferase assays, 30UTR of Ric-
tor was ampliﬁed using gene speciﬁc primers (Table S2). The frag-
ment spanning putative binding site for miR-34a was cloned into
luciferase plasmid, pMIR-REPORT miRNA Expression Reporter Vec-
tor (Life Technologies, Grand Island, NY, USA). The speciﬁcity of the
30UTR Rictor clone was conﬁrmed by DNA sequencing.
2.5. Proliferation assay
Cell proliferation was measured by MTT assay as described pre-
viously [26]. Brieﬂy, cells were plated at density of 1  103 cells per
well in 96 well plate (BD Biosciences, Bedford, MA, USA). Cell
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val, 20 lL of MTT (5 mg/mL) (Sigma–Aldrich) was added to each
well and the plate was incubated for 4 h at 37 C in a CO2 incuba-
tor. The Formazan crystals formed were dissolved in dimethyl sulf-
oxide (DMSO) (Sigma–Aldrich) and absorbance of each well was
measured at 570 nm in a Bio-Rad micro-plate reader 680 (Bio-
Rad, Hercules, CA, USA).
2.6. Flow cytometry
The cell cycle kinetics of parental and transfected cells was
determined using ﬂow cytometry. For this, cells were harvested
and washed with cold 1 PBS (Phosphate Buffered Saline)
(HiMedia, Mumbai, MH India) buffer and ﬁxed with 75% ethanol
for 30 min on ice. Further, cells were washed 3 times with cold
1 PBS and incubated with 50 lg/mL of propidium iodide (PI)
(Invitrogen) and 10 lg/mL of DNase-free RNase A in 500 lL of 1
PBS for 30 min at 37 C. Later, cells were re-suspended in 500 lL
of 1 PBS and acquired on FACSCalibur (BD Bioscience). Cells were
acquired and DNA histograms were generated and analyzed by
CellQuest™ Pro 5.2.1 software (BD Biosciences). For cell surface
marker analyses for CD44 expression, cells were harvested from
culture and washed in cold 1 PBS buffer and ﬁxed with 75% eth-
anol for 30 min on ice. Further, cells were washed with cold 1 PBS
and blocked with blocking buffer (5% BSA) for 30 min at 4 C. Cells
were incubated with primary antibody against CD44 (Chemicon
International Billerica, MA, USA) for 1 h followed by incubation
with secondary antibody Alexa Fluor 488 (Invitrogen). The cells
were then washed with cold 1 PBS, re-suspended in 500 lL of
cold 1 PBS and acquired on FACSCalibur (BD Bioscience). DNA
histograms were generated and analyzed by CellQuest™ Pro 5.2.1
software (BD Bioscience).
2.7. Immuno-staining
The parental and transfected cells were seeded in 24 well plates
(BD Bioscience) for 48 h. Later, cells were ﬁxed with 3.7% para-
formaldehyde (PFA) (Sigma–Aldrich), for 10 min at room tempera-
ture followed by permeabilization using 0.01% Triton X-100
(Sigma–Aldrich). Cells were blocked with 5% BSA (Bovine Serum
Albumin) and incubated with primary antibody to Ki67 (1:100;
Rabbit) (Chemicon International) for 2 h at room temperature fol-
lowed by incubation with anti-rabbit Alexa Fluor 594 (1:100)
(Invitrogen) for 45 min. The nuclei were stained with DAPI (40,6-
diamidino-2-phenylindole) (Sigma–Aldrich) for 10 min and then
mounted on slides with help of mounting medium containing 1%
DABCO (1,4-diazabicyclo [2.2.2] octane) (Sigma–Aldrich). The
immuno-staining was visualized using confocal microscope Leica
TCS SP5II (Leica Microsystems CMS, GmbH, Germany).
2.8. Apoptosis assay
Caspase-3, Caspase-9 and PARP (Poly ADP-ribose polymerases)
activities were assayed using apoptotic sampler kit (Cell Signaling
Technology, Denvers, MA, USA) as per manufacturer’s instructions.
Parental and transfected cells were harvested, washed with 1 PBS
buffer, ﬁxed, permeabilized using 0.01% Triton X-100 (Sigma–
Aldrich) and blocked with blocking buffer (5% Bovine Serum Albu-
min) for 30 min. Further, cells were individually incubated with
primary antibodies to Caspase 3, Caspase 9 and PARP (1:100) for
1 h followed by incubation with anti-Rabbit Alexa Fluor 594
(1:100) (Invitrogen) for 45 min. Finally, cells were resuspended
in 0.5 mL of 1 PBS and acquired on FACSCalibur ﬂow cytometer
(BD Bioscience). The data was analyzed with Cell Quest Pro analy-
sis software 5.2.1 (BD Bioscience).2.9. Xenograft mouse model
The animal experiments were approved by Institutional Animal
Ethical Committee (IEC) of NCCS and the experimental procedures
followed were according to animal ethical guidelines of NCCS. For
in vivo tumorigenicity assay, 6–8 weeks old NOD-SCID mice were
used. For subcutaneous injections, 1  106 cells of both EV cells
and miR-34a expressing cells suspended in 50 lL of 1 PBS were
injected into the ﬂanks of mice (n = 9). Animals were monitored
for tumor development and end point tumor volume was calcu-
lated using formula 4/3 p (
p
major axis/2 minor axis/2).
2.10. Invasion assay
Invasion assay was performed using Matrigel Invasion Cham-
bers (BD Biosciences) with inserts of 8 lm pore size in 24 well
plates according to manufacturer’s protocol. Brieﬂy, 5  103 cells
in 0.5 mL of serum free DMEM medium were seeded on insert
comprised of Matrigel. After incubation for 24 h, the non-invading
cells from upper chamber were removed mechanically and inva-
sive cells were ﬁxed and stained with 0.1% (weight/volume) crystal
violet stain (Sigma–Aldrich). Stained cells were counted from 10
different microscopic ﬁelds and the images were acquired using
Olympus IX51 microscope (Olympus Imaging PA, USA). The data
was quantiﬁed with Image J 1.47 software.
2.11. Western blot analysis
To extract proteins, cells were harvested and incubated on ice
for 20 min with M-PER reagent (Thermo Scientiﬁc Rockford, lL,
USA) containing 1 protease inhibitor cocktail (Sigma–Aldrich)
The cells were centrifuged at 12,000g for 20 min and the superna-
tant fractions were collected for western blot analysis. Equal
amounts of protein were loaded on SDS–PAGE gel and transferred
on to PVDF membranes (Millipore). The blots were probed with
various primary antibodies: Rictor, CyclinD1 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), b-catenin, GSK-3b, p-AKT, AKT,
c-Myc (Cell Signaling Technology), and Actin (MP Biomedicals,
OH, USA) at 1:1000 dilution followed by incubation with species
speciﬁc horseradish peroxidase conjugated secondary antibodies
(1:2000). The proteins were detected by Super Signal protein
detection kit (Thermo Scientiﬁc). Target protein levels were nor-
malized with actin and quantiﬁed by Image J Software.
2.12. Luciferase assay
To determine if there was a direct interaction of miR-34a with
30UTR of Rictor, we co-transfected pMIR-REPORT (Applied Biosys-
tem) luciferase vector and pMIR-REPORT containing Rictor 30UTR
in both EV and miR-34a expressing cells. After 48 h of transfection,
luciferase activity was measured by using Dual-Glo Luciferase
Assay system (Promega, Madison, WI). Luciferase activity was nor-
malized with Renilla activity.
2.13. TOPﬂash/FOPﬂash reporter assay
To determine the effects of miR-34a overexpression on Wnt/b-
catenin activity, we performed transfection assays with b-catenin/
TCF reporter plasmids according to manufacturer’s protocol
(Millipore Billerica, MA, USA). Brieﬂy, 1  104 cells were tran-
siently transfected with either 2 lg of pTOPﬂash (TCF Reporter
Plasmid) or pFOPﬂash (mutant, inactive TCF binding site) plasmids
(Millipore) and 0.5 lg of pSV40-Renilla plasmid as an internal con-
trol (Promega) using Lipofectamine 2000 (Invitrogen) for 48 h.
Both Fireﬂy and Renilla luciferase activities were measured with
Fig. 1. Characterization of glioma stem cell-lines for mesenchymal sub-type. Quantitative Real time PCR (qRT-PCR) analysis for expression of mesenchymal markers RELB,
Twist1, ZEB2 and COL5A1 (A) and proneural markers PDGFRa and NKX2-2 (B) in HNGC-2 and NSG-K16 cell-lines. Expression levels were normalized to normal human brain
and were set to one. 18S rRNA gene expression served as internal control. Data represents average of three independent experiments. Fold change was calculated by 2DDCt
method. Error bar represents the mean ± SEM. P value was calculated by one way ANOVA and Student’s t test (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.0001). (C) Flow cytometry analyses
for expression of cell surface marker CD44 in HNGC-2 and NSG-K16 cells (representative proﬁle).
488 S.S. Rathod et al. / FEBS Open Bio 4 (2014) 485–495a Glomax luminometer (Promega) using Dual-Glo Luciferase Assay
System (Promega) according to manufacturer’s instructions.
2.14. Bioinformatics analysis
Candidate targets of miR-34a were screened from publically
available microRNAs targets using TargetScan (http://www.target-Fig. 2. Differential expression of miR-34a in tissues and cell lines. Quantitative Real tim
grade (n = 19) gliomas. Expression levels were normalized to normal human brain and
Expression levels were normalized to normal human brain and were set to one. (C) HN
rRNA served as an internal control. Fold change was calculated by 2DDCt method. Err
calculated one way ANOVA and Student’s t test (⁄⁄P < 0.01, ⁄⁄⁄P < 0.0001).scan.org/), miRanda (http://www.microrna.org/), PicTar
(pictar.mdc-berlin.de) and miRDB (http://www.mirdb.org) dat-
abases. The miR-34a seed sequence and Rictor 30UTR alignment
was generated by miRanda (http://www.microrna.org/). Kaplan–
Meier survival plot for Rictor gene expression data was generated
by using REMBRANDT (REpository for Molecular BRAin Neoplasia
DaTa) [27].e PCR (qRT-PCR) analysis of miR-34a expression in (A) low grade (n = 13) and high
were set to one. (B) Expression in glioma stem cell-lines – HNGC-2 and NSG-K1.
GC-2 and NSG-K16 cell-lines transfected with miR-34a and empty vector (EV). 18S
or bar represents the mean ± SEM of three independent experiments. P value was
Fig. 3. Effects of miR-34a overexpression on cell proliferation and cell cycle. (A) MTT assay of miR-34a over-expressing and EV cells (B) Immuno-staining for proliferation
marker Ki67 in miR-34a and EV cells. Nuclei were stained by DAPI (BLUE) stain and Ki67 by AlexFluor 594 (RED). (C) Flow cytometry analysis of EV and miR-34a cells showing
distribution of cells in different phases of cell cycle (Upper Panel). (D)The lower panel shows the percentage cells in different phases of cell cycle as represented as
means ± SEM.
Fig. 4. MiR-34a induces caspase dependent apoptosis. (A) HNGC-2 and NSG-K16 cells analyzed for cleaved caspase 3, caspase 9, and PARP by ﬂow cytometry. The peaks for
HNGC-2 and NSG-K16 EV cells are depicted by black line graph and for miR-34a glioma cells by red line graph. The multiple peaks in mir-34a expressing cells indicate cells in
early and late apoptosis. (B) Quantitative representation of ﬂow cytometry data in (A) showing relative expression of cleaved caspase 3, caspase 9 and PARP in HNGC-2 and
NSG-K16 miR-34a transfected and EV control cells. Each bar represents the means ± SEM of 3 independent experiments. ⁄P < 0.05, ⁄⁄⁄P < 0.001 vs EV cells generated using t-
test.
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Fig. 5. Over-expression of MiR-34a suppresses tumor growth in vivo and inhibits invasion in vitro. (A). Representative images of NOD SCID mice (n = 9) showing tumors
formed with HNGC-2-EV (R) and miR-34a cells (L) (a). Tumors excised after 4 weeks are represented in (b) and quantiﬁed in (c). (B) Phase contrast micrographs of Invasion
assay displaying migratory property of HNGC-2 – EV and miR-34a cells performed using invasion chambers of 8 l and stained with crystal violet after 24 h (10
magniﬁcation) (a) and quantiﬁed in (b). The percentages of invading cells were determined by considering migration of HNGC-2 and NSG-K16–EV cells as 100%. Data
represents means ± SEM (n = 3) and P value calculated by Student’s t test (⁄P < 0.05, ⁄⁄⁄P < 0.0001).
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All statistical analysis was done using GraphPad PRISM version
5.0 (GraphPad Software, Inc., La Jolla, CA, USA). All experiments
were performed in triplicates. Data is represented as Means ± SEM
(Standard Error of Means). Student’s t test was used to calculate
statistical signiﬁcance between two groups. One-way ANOVA
was used for multiple group comparisons (⁄P < 0.05; ⁄⁄P < 0.01;
⁄⁄⁄P < 0.0001).
3. Results
3.1. Glioma stem cell-lines HNGC-2 and NSG-K16 display enriched
mesenchymal GBM phenotype
The HNGC-2 and NSG-K16 cell-lines developed by us as glioma
stem cell-lines were classiﬁed into speciﬁc GBM sub-types using
molecular markers. This analysis was performed by qRT-PCR
wherein the expression of various mesenchymal and pro-neural
markers was analyzed and compared to their expression in normal
brain tissues. Characteristically, both cell-lines displayed positivity
for expression of mesenchymal markers like- RELB, Twist1, ZEB2
and COL5A1 (Fig. 1A); and showed absence of expression for pro-
neural related genes i.e., PDGFRA and NKX2-2 (Fig. 1B). The CD44
expression in both HNGC-2 and NSG-K16 cell-lines was high as
determined by ﬂow cytometry (Fig. 1C) signifying their aggressive
nature. On the basis of marker analyses we conﬁrmed that these
cell-lines belonged to the mesenchymal GBM sub-type.
3.2. MiR-34a is down-regulated in glioma tumor tissues and glioma
cell-lines
We performed stem loop reverse transcription PCR (RT-qPCR) to
quantify miR-34a expression in glioma tumor tissues and cell-
lines. For this, we compared expression of miR-34a in both low
(n = 13) and high grade (n = 19) glial tumors with expression in
normal brain tissues (n = 3) (Fig. 2A). A greater than 10-fold
decrease in miR-34a levels was demonstrated in both low
(P < 0.0001) and high grade glioma tumor tissues (P < 0.0001). A
similar pattern of lowered expression of miR-34a was evident in
GBM cell lines – HNGC-2 (P = 0.0002) and NSG-K16 (P = 0.0002)(Fig. 2B). To determine, the functional signiﬁcance of miR-34a in
glioma progression, we over-expressed miR-34a in glioma stem
cell lines HNGC-2 and NSG-K16 cells and generated miR-34a over-
expressing stable cell lines (Fig. 2C). Expectedly, miR-34a was
over-expressed in HNGC-2 (P < 0.01) and NSG-K16 (P < 0.01) cells
as compared to their respective EV Control cells. Here, EV repre-
sents control glioma stem cells transfected with empty vector.
3.3. MiR-34a inhibits glioma cell proliferation induces cell cycle arrest
and apoptosis in vitro
The effects of ectopic over-expression of miR-34a on cell prolif-
eration for glioma stem cell-lines HNGC-2 and NSG-K16 was deter-
mined by MTT assay. Overexpression of miR-34 led to inhibition of
cell proliferation of both HNGC-2 and NSG-K16 cells as compared
to EV control cells (Fig. 3A) analyzed over a 5 day period by MTT
assay. Similarly, miR-34a caused decrease in positivity for Ki67
expression in glioma cells as compared to EV cells (Fig. 3B). Cell
cycle kinetics using ﬂow cytometry indicated that miR-34a signif-
icantly induced cell cycle arrest in both HNGC-2 and NSG-K16 cells
(Fig. 3C). The percentages of cells in G0/G1 phase was signiﬁcantly
increased by miR-34a from 55.19 ± 7.4% to 76.48 ± 8.6% in HNGC-2
cells and from 49.03 ± 1.7% to 75.46 ± 5.6% in NSG-K16 cells as
compared to their EV counterparts (Fig. 3D). Consequent to G0/
G1 arrest, there was an extensive decrease in S phase population
by about 2-fold in both HNGC-2 and NSG-K16 cells due to miR-
34a (Fig. 3D). The apparent G0/G1 arrest and decrease in S phase
population led us to determine possible role of miR-34a in induc-
ing apoptosis. MiR-34a over-expression in both cell-lines caused
enhanced apoptosis wherein by ﬂow cytometry we detected pres-
ence of activated Caspases 3 and 9 along with cleaved PARP in both
HNGC-2 and NSG-K16 (P 6 0.01) cells. The miR-34a overexpression
led to distinct peaks representing populations in early and late
apoptosis in both cell-lines (Fig. 4A and B), signifying potential of
miR-34 to induce apoptosis.
3.4. MiR-34a suppresses tumor growth and invasion of glioma stem
cells
The growth suppression caused by miR-34a over-expression in
glioma stem cells led us to evaluate its effect on tumor forming
Fig. 6. Rictor is a target for miR-34a (A) Alignment of miR-34a seed sequence with 30UTR of Rictor. (B) Western blot analysis of HNGC-2 and NSG-K16 cells expressing miR-
34a and EV and probed for Rictor. The band intensities were calculated with help of Image J software. Actin served as loading control. (C) Schematic representation of Renilla
Luciferase Reporter assay with wild-type 30UTR of Rictor in luciferase experiment. Dual Luciferase assay showing relative luciferase activity in HNGC-2 (D) and NSG-K16 (E)
cells expressing EV and miR-34a. Renilla luciferase activity was normalized with ﬁreﬂy luciferase activity as control for transfection. (F) MTT assay showing effect of Rictor
siRNA on proliferation of HNGC-2 cells. (G) Flow cytometry proﬁle showing distribution of cells in different phases of cell cycle in HNGC-2 and HNGC-2 Rictor siRNA cells.
Error bar represents the means ± SEM and (n = 3). P value is calculated by Students t test (⁄⁄P < 0.005).
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miR-34a expressing cells (106) subcutaneously into NOD/SCIDmice
and monitored tumor growth for 45 days. The HNGC-2 and NSG-
K16-EV cells were able to form detectable tumors within 7 days.
However, miR-34a over-expressing cells formed signiﬁcantly
reduced tumors as compared to EV cells (Fig. 5A, a and b). The
tumors with HNGC-2-miR-34a cells were about 6 folds smaller as
compared to EV induced tumors (P < 0.05) (Fig. 5A, c). The notable
reduction in tumor volume reafﬁrmed the tumor suppressive func-
tion of miR-34a. MiR-34a also affected invasiveness of glioma cells
as was apparent from matrigel invasion chamber assay. The miR-
34a overexpressing cells possessed decreased invasive potential in
matrigel assay as compared to EV cells (P < 0.0001) (Fig. 5B, a and
b). These effects on tumor growth inhibition and invasion potential
on glioma cells reiterated role of miR-34a as growth suppressor.
3.5. Rictor is a target for miR-34a
MicroRNAs regulate gene expression at post-transcriptional
level either by inhibiting translation of complementary mRNAsand by targeting them for degradation [4]. We used an in silico
based approach for identiﬁcation of novel putative targets for
miR-34a that could be responsible for mediating effects on growth
suppression of glioma cells. We used three target databases viz:
Miranda (http://www.microrna.org/microrna/home.do), Target-
Scan (http://www.targetscan.org/), and PicTar (http://pictar.
mdc-berlin.de/) to identify putative targets for miRNA action. Data
from each of these databases led us to identify Rictor as one of the
common target for miR-34a. It possessed complementary seed
sequence at 30UTR region for miR-34a and displayed a mirSVR
score of 0.6782 (Fig. 6A). Rictor is a core component of the dis-
tinct mTOR protein complexes, mTORC2. The mammalian target
of rapamycin (mTOR) plays a critical role in the positive regulation
of cell growth and survival primarily through direct interaction
with raptor (forming mTORC complex 1; mTORC1) or Rictor
(forming mTOR complex 2; mTORC2) [28]. The mTORC2 complex
with Rictor is a critical regulator of AKT, a critical effector of PI3K
signaling pathway and found to be activated in all patients with
glioblastoma [18]. Our earlier studies demonstrated higher levels
of Rictor in increased glioma grades [29]. In response to miR-34a
Fig. 7. MiR-34a is negative regulator of AKT andWNT signaling pathway. (A) Western blot analyses of HNGC-2-EV and miR-34a cells. Actin was used as loading control; band
intensities were calculated by Image J software and normalized to actin. (B) b-Catenin staining in HNGC-2-EV and miR-34a cells, detected with help of goat anti-rabbit Alexa
Flour 594 (Red). Nuclei were stained with DAPI (Blue). (C) b-catenin/TCF reporter assay using dual luciferase reporter system. The normalized luciferase activity was used to
estimate ratio of TOPﬂash to FOPﬂash and represented as a bar graph by considering EV luciferase activity as 1. Data are presented as average values ± SEM (n = 3) and P value
is calculated by Student’s t test (⁄P < 0.05).
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signiﬁcant down-regulation of Rictor at protein level indicating it
to be a functional target of miR-34a (Fig. 6B). Next, by Luciferase
reporter assay we conﬁrmed that Rictor was a direct target of
miR-34a in glioma cells. The schematic of luciferase assay is shown
in Fig. 6C. Our data indicated that miR-34a directly bound to 30UTR
of Rictor and suppressed the luciferase activity in HNGC-2 and
NSG-K16 cells (P < 0.05) (Fig. 6D and E). This data indicated that
miR-34a directly targets Rictor in glioma stem cells.
3.6. Inhibition of Rictor mimics effects of miR-34a over-expression
To conﬁrm functional role of Rictor as a miR-34a target involved
in mediating effects on cell growth and tumorigenicity in glioma
cells, we performed Rictor knock-down experiments. For this we
performed a siRNA mediated knock down of Rictor expression in
HNGC-2 cells and analyzed whether loss of Rictor activity mim-
icked the miR-34a effects on glioma stem cells. Here, siRNA against
Rictor was transiently transfected into HNGC-2 cells and transfec-
ted cells were analyzed for effects on cell proliferation by MTT
assay and cell cycle kinetics by ﬂow cytometry. Rictor siRNA inhib-
ited cell proliferation of glioma cells as examined by MTT assay
(Fig. 6F). Also, Rictor siRNA caused cell cycle arrest leading to
increased G0/G1 population in siRNA treated cells (Fig. 6G) as com-
pared to EV cells. These experiments conﬁrmed that Rictor was a
functional target of miR-34a in glioma stem cells.3.7. MiR-34a affects the PI3K/AKT and WNT/b-Catenin signaling
pathway in glioma
Our in vitro and in vivo data provided evidences that miR-34a
functioned as a tumor suppressor in high grade gliomas. The ecto-
pic over expression of miR-34a led to decreased aggressiveness in
GBM cell-lines by targeting Rictor, an integral component if the
mTORC2 complex. Rictor along with mTORC2 leads to the phos-
phorylation of AKT at serine 473 (ser473) and activates p-AKT
[30]. Further, we analyzed whether, over-expression of miR-34a
led to activation of AKT signaling pathway. We found a signiﬁcant
down-regulation of p-AKT by miR-34a in HNGC-2 cells as com-
pared to EV cells causing activation of glycogen synthase kinase
(GSK)-3b. As GSK-3b functions as a negative regulator of b-catenin
stabilization, AKT phosphorylation of GSK-3b leads to b-catenin
stabilization and nuclear accumulation. Characteristically, we
found a decreased expression of beta-catenin in miR-34a HNGC-2
cells by Western blotting (Fig. 7A). Importantly, complete lack of
nuclear beta-catenin expression was obtained by confocal micros-
copy in miR-34a over-expressing HNGC-2 cells (Fig. 7B). Similarly,
the luciferase reporter assay was used to evaluate Wnt activity.
There was 3.3-fold decrease in Tcf/Lef activity (P < 0.05) in
HNGC-2-miR-34a cells as compared to the control cells (Fig. 7C).
The effects of miR-34a leading to inhibition of Wnt signaling
caused reduced levels of target proteins of Wnt pathway- Cyclin
D1 and c-Myc. We have earlier shown that Wnt signaling is an
Fig. 8. Proposed model depicting mechanism for action of miR-34a in glioma cells.
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present data indicates that Rictor is a direct target of miR-34a.
Hence, inhibition of miR-34a, through up-regulation of Rictor
causes activation of AKT-GSK-3b axis in glioma stem cells leading
to activation of WNT/b-catenin signaling pathway. The effects of
miR-34a loss on cellular signaling in glioma stem cells leading to
enhanced cell proliferation, aggressiveness and tumorigenicity is
proposed in Fig. 8.
4. Discussion
Heterogeneity within the tumor, its deep seated location in the
brain, aggressive nature and angiogenic behavior makes glioblas-
toma a difﬁcult CNS tumor to treat. Even though multimodal ther-
apies increase patient survival, GBM prognosis remains challenging
[31]. It is believed that the phenotypic and functional heterogene-
ity within the tumor arises due to presence of a small tumor initi-
ating cell population that propels the tumor.
We have developed in vitro cell culture model systems that
mimic glioma tumor progression. These developed cell systems
possess a great potential in understanding the signaling events that
lead to the advanced disease phenotype in glioma [24,25,32]. The
HNGC-2 and NSG-K16 cell-lines used in this study are well charac-
terized by us as glioma stem cell-lines [24,25]. We used these cell-
lines to identify a set of miRNA’s that were differentially expressed
in glioma stem cell-lines as compared to neural stem cells. We ear-
lier demonstrated function of one of the miRNA’s, miR-145 with
tumor suppressive role in GBM with Sox9 and Adducin3 as itsnovel targets [8]. In the present study, we report functional signif-
icance of miR-34a and report Rictor as a novel target for miR-34a
using the tumor progression model of HNGC-1 to HNGC-2 cell sys-
tem developed by us.
It is well established that microRNAs can target multiple genes
including oncogenes, and their interactions are cell type speciﬁc
[33]. Hence, identiﬁcation of differentially expressed microRNAs
and their context dependent targets is of great help in uncovering
the network of biological processes governing speciﬁc phenotype.
MiR-34a is reported to be signiﬁcantly down-regulated in multiple
cancer types and its expression correlates with patient survival. It
is localized on chromosome 1p36 and its down-regulation is asso-
ciated with multiple chromosomal abnormalities like frequent
deletion of chromosome 1p36, p53 mutation and CpG methylation
of miR-34a promoter itself [34]. Moreover, deregulation of miR-
34a affects many biological processes like cell cycle, senescence,
apoptosis, differentiation and development [35–37]. These ﬁndings
emphasize requirement for comprehensive studies to conﬁrm
molecular targets for miR-34a and understand its functional con-
tribution to glioma progression. The role of miR-34a as a tumor
suppressor in glioma is known [14,38,39] wherein its targets are
several oncogenes like c-Met, Notch1, Notch2 and CDK6 [14,40].
Signiﬁcantly, p53 is an important target for miR-34a and it is
shown that expression of miR-34a in mutant p53 is lower as com-
pared to those cell lines bearing wild type p53. It is suggested that
role of miR-34a in tumor progression may be closely associated
with p53 mutation and is inversely correlated to Bcl-2 expression
[6].
494 S.S. Rathod et al. / FEBS Open Bio 4 (2014) 485–495In this report, we demonstrate that miR-34a is down-regulated
in higher grade gliomas (GBM) and glioma stem cell-lines like –
HNGC-2 and NSG-K16. More importantly, we here report identiﬁ-
cation of Rictor as a novel target for miR-34a. We further demon-
strate that over-expression of Rictor in glioma stem cells causes
activation of AKT signaling. This via enhancement of GSK-3b axis
causes nuclear localization of beta-catenin and over-expression
of Wnt target genes- CyclinD1 and c-myc. We show that activation
of Wnt cellular signaling pathways causes effects on tumorigenic-
ity and invasiveness in GBM.
Invasion is the hallmark of high grade glioma speciﬁcally shown
by aggressive mesenchymal GBM phenotype [22,41]. Recently,
miR-21 and miR-10b are positively correlated with glioma inva-
sion and miR-34a is listed as one of the anti-invasive microRNAs
[5,42,43]. In this study, we characterized the glioma stem cell-lines
HNGC-2 and NSG-K16 and showed them to possess the mesenchy-
mal GBM phenotype (Fig. 1). Over-expression of miR-34a in these
glioma stem cell-lines reduced their invasive potential by more
than 80% signifying an important role for it in glioma invasion.
Our identiﬁed miR-34a target, Rictor is signiﬁcantly involved in
glioma tumor progression. It is overexpressed in many cancers and
is involved in gliomagenesis via mTOR-dependent and mTOR-inde-
pendent mechanisms [44–46]. Rictor expression is essentially cor-
related with aggressiveness of GBM, mainly acting by modulating
MMP9 activity. Our previous study has reported that Rictor
enhanced MMP9 activity in glioma cell-lines LN-18 and LN-229
via activation of RAF-1-MEK-ERK pathway [29]. With help of REM-
BRANDT data [27] we generated the Kaplan Meier survival graph
for Rictor gene expression. Our analyses showed that 93 patients
with higher expression of Rictor had lower survival as compared to
patients that showed intermediate Rictor expression (P = 2.47E08,
Supplementary Fig. S1). It is evident from the survival curve that
Rictor expression was negatively correlated with survival of
patients and played an important role in glioma progression.
Earlier, we showed that Wnt3a mediated Wnt/b catenin signal-
ing was an essential tumorigenic driver in glioma stem cells, indi-
cating that Wnt3a was an oncogene and novel therapeutic target in
glioma [25]. Interestingly, here our data shows that miR-34a over-
expression down-regulates b-Catenin activity and this was con-
ﬁrmed by us with TOP/FOP ﬂash luciferase assay. The GSK-3b
kinase, acts as negative regulator of WNT/b Catenin signaling path-
way wherein it induces b-Catenin phosphorylation leading to its
proteasome mediated degradation [47]. The interplay between
AKT and WNT signaling pathways through AKT-GSK-3b axis was
studied previously in skeletal development; twist mediated epi-
thelial-mesenchymal transition (EMT) in cancer stem cells and also
in glioma [48–50]. Based on our data, we propose a model of action
of miR-34a in glioma stem cells (Fig. 8). Our study demonstrates
that miR-34a functionally targets Rictor and acts as tumor suppres-
sor by suppressing AKT followed by WNT signaling pathway. This
has crucial implications on cell proliferation, invasion and tumor
progression in GBM. Our data provides experimental evidence to
suggest that miR-34a is an important therapeutic target for glioma
stem cells and thus targeting it has a great potential in inhibiting
glioma progression and preventing recurrence thereby improving
long term survival in glioblastoma.
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